Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of BioMarin Pharmaceutical („BioMarin“ or the
„Company“) (NASDAQ: BMRN) resulting from allegations that BioMarin might have issued misleading information to the investing public.

If you purchased BioMarin securities, and/or would like to discuss your

Post Views: 160

PREVIOUS ARTICLE

Pangyo Technovalley’s 100 IT & CT Special – MIK HOT SPOT Online Exhibition to open on September 11

NEXT ARTICLE

FONAR Announces Fiscal 2020 Financial Results

Related Post

BRISTOL MYERS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company – BMY

BRISTOL MYERS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company – BMY
/ Okt 8
Dax aktuell: Dax startet mit neuen Verlusten – Börsenmonat September rückt Jahrestief in den Fokus

Dax aktuell: Dax startet mit neuen Verlusten – Börsenmonat September rückt Jahrestief in den Fokus
/ Sep 1
Nikkei, Topix und Co.: Asiatische Börsen erstarken – Rohstoffpreise erreichen Höchstwerte

Nikkei, Topix und Co.: Asiatische Börsen erstarken – Rohstoffpreise erreichen Höchstwerte
/ Mai 6